alexa Could Sorafenib Disclose New Prospects as Bridging Ther
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Could Sorafenib Disclose New Prospects as Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma?

Alessandro Vitale1*, Freddy Salinas2, Giacomo Zanus1, Giuseppe Lombardi3, Marco Senzolo4, Francesco Russo4 and Umberto Cillo1
1Unità di Chirurgia Epatobiliare e Trapianto Epatico, Azienda - Università di Padova, Italy
2U.O. di Medicina - Centro di Epatologia, Casa di Cura Giovanni XXIII, Monastier (TV), Italy
3Istituto Oncologico Veneto, IRCCS, Padova, Italy
4Divisione di Gastroenterologia, Azienda - Università di Padova, Italy
Corresponding Author : Alessandro Vitale
Unità di Chirurgia Epatobiliare e Trapianto Epatico
Dipartimento di Chirurgia Generale e Trapianti
Via Giustiniani 2, 35128 Padova, Italy
Tel: 00(39)-0498212236
Fax: 00(39)-0498211816
E-mail: [email protected]
Received October 23, 2013; Accepted November 12, 2013; Published November 20, 2013
Citation: Vitale A, Salinas F, Zanus G, Lombardi G, Senzolo M, et al. (2013) Could Sorafenib Disclose New Prospects as Bridging Therapy to Liver Transplantation in Patients with Hepatocellular Carcinoma? J Liver 2:134. doi:10.4172/2167-0889.1000134
Copyright: © 2013 Vitale A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background-Aim: There are few data on the use of sorafenib as bridging therapy for patients with Hepatocellular Carcinoma (HCC) waiting for Liver Transplantation (LT). Methods: Six HCC patients were treated with sorafenib before LT at our Institution following the Italian Drug Agency guidelines: they had well compensated cirrhosis (Child-Pugh class A), intermediate stage HCC, good general conditions (performance status 0) and they were not suitable for loco-regional therapies. Results: Three patients received sorafenib until LT, whereas the other three cases required treatment discontinuation before LT. During the post-surgery period no deaths and anastomotic complications were observed. The four patients receiving Sorafenib for more than 2 months before LT were recurrence-free 27 to 41 months after surgery. Conversely, tumor recurrence leading to patient death was found in the other 2 cases. Conclusion: We think that these findings justify the start of a phase II study in a larger patient population.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version